Abstract

application's abstract): The AIDS Clinical Trials Unit (ACTU) at Case Western Reserve University (CWRU) has been in operation since 1987 and has established a track record of high-level accrual and performance of HIV treatment trials and both administrative and scientific leadership of the Adult AIDS Clinical Trials Group (AACTG). For all periods of evaluation by the AIDS Clinical Trial Group (ATCG), the CWRU ACTU has been rated among the top few within the AACTG for every level of performance. For the next period of award, the CWRU ACTU proposes to continue its high-level accrual and performance of treatment trials that support the agenda the HIV Diseases, Immunology and Opportunistic Diseases Research Agenda Committees. In addition, the CWRU ACTU will contribute the expertise of its faculty to leadership of the AACTG effort to examine the immunopathogenesis of HIV disease through the development and implementation of pathogenesis-based treatment protocols. The CWRU ACTU will also bring to the ACTG the expertise of its faculty in the laboratory monitoring of HIV disease through its Immunology Service Laboratory and other research laboratories within the institution.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI025879-17
Application #
6696324
Study Section
Special Emphasis Panel (ZAI1-PSS-A (S1))
Program Officer
Germuga, Donna E
Project Start
1987-09-30
Project End
2008-12-31
Budget Start
2004-01-01
Budget End
2008-12-31
Support Year
17
Fiscal Year
2004
Total Cost
$1,978,951
Indirect Cost

  Institution

Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106

  Publications

Chang, J Judy; Woods, Matt; Lindsay, Robert J et al. (2013) Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Infect Dis 208:830-8
Kyeyune, Fred; Nankya, Immaculate; Metha, Samar et al. (2013) Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS 27:1899-909
Imamichi, Hiromi; Degray, Gerald; Asmuth, David M et al. (2011) HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS 25:159-64
Anthony, D D; Umbleja, T; Aberg, J A et al. (2011) Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine 29:3558-63
Tebit, Denis M; Lobritz, Michael; Lalonde, Matthew et al. (2010) Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol 84:9817-30
Lok, Judith J; Bosch, Ronald J; Benson, Constance A et al. (2010) Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS 24:1867-76
Kalayjian, Robert C (2010) The treatment of HIV-associated nephropathy. Adv Chronic Kidney Dis 17:59-71
Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Sereti, Irini; Dunham, Richard M; Spritzler, John et al. (2009) IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 113:6304-14

Showing the most recent 10 out of 116 publications